Alzheimer's Disease Treatment 2026: Anti-Amyloid Antibodies and Beyond
The Anti-Amyloid Era in Alzheimer's Treatment
After decades of failed clinical trials, anti-amyloid monoclonal antibodies have demonstrated clinically meaningful slowing of cognitive decline in early Alzheimer's disease. Lecanemab (Leqembi) and donanemab represent the first disease-modifying therapies to achieve robust Phase 3 efficacy, fundamentally changing the treatment paradigm for this devastating condition.
Lecanemab: Clarity AD Trial Results
The Clarity AD trial enrolled 1,795 participants with early Alzheimer's disease (MCI or mild dementia with confirmed amyloid pathology). Lecanemab reduced decline on the CDR-SB by 27% compared to placebo over 18 months (difference of -0.45 points, p < 0.001). Brain amyloid was reduced to below the threshold for positivity in 68% of participants.
ARIA Monitoring: The Safety Imperative
Amyloid-related imaging abnormalities (ARIA) are the primary safety concern with anti-amyloid therapies. ARIA-E (edema) occurred in 12.6% of lecanemab-treated patients, with most cases asymptomatic and detected on routine MRI monitoring. APOE4 homozygotes have significantly higher ARIA risk. Current monitoring protocols require MRI at baseline, before doses 5, 7, and 14, and with any new neurological symptoms.
Sponsored
Patient Selection and Practical Implementation
Appropriate patient selection requires: confirmed amyloid positivity (via PET or CSF), early-stage disease (MCI or mild dementia), APOE genotyping for risk stratification, baseline MRI showing no more than 4 microhemorrhages and no macrohemorrhage, and adequate anticoagulation status assessment. The infrastructure requirements including infusion centers, MRI access, and amyloid testing capacity remain significant barriers to implementation.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.